CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE
... | December 12, 2021

Related Keywords

Georgia ,United States ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Atlanta ,American ,Liud Acalabrutinib ,Acerta Pharma ,National Cancer Institute ,American Society Of Clinical Oncology ,Astrazeneca Pharmaceuticals ,American Society Of Hematology ,Astrazeneca ,Leukaemia Foundation ,Patient Care Health Information ,National Cancer Incidence ,American Cancer Society ,American Society ,Annual Meeting ,Acid Reducing Agents ,Prescribing Information ,Clinical Oncology ,Independent Review Committee ,Rare Diseases ,Year Follow Up ,Rituximab Plus Idelalisib ,Refractory Chronic Lymphocytic Leukemia ,Chronic Lymphocytic ,Bruton Tyrosine Kinase Inhibitor ,Related Adverse Events ,Head To Trial ,Acalabrutinib Versus Ibrutinib ,Previously Treated Chronic Lymphocytic Leukemia ,Patient Care ,Health Information ,Idelalisib Plus Rituximab ,Bendamustine Plus Rituximab ,Chronic Lymphocytic Leukemia Treatment ,Disease Cancer ,Life Lost ,Years Lived ,Disability Adjusted Life Years ,Economic Burden ,Chronic Lymphocytic Leukemia ,Oral Targeted ,Randomized Trial ,Acalabrutinib Versus Idelalisib Plus Rituximab ,Versus Ibrutinib ,Previously Treated Subjects With High Risk ,First Randomized Phase ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,Trial ,Data ,Also ,Resented ,It ,Sh ,Howed ,Patients ,N ,Ibrutinib ,Xperienced ,Higher ,Burden ,F ,Madverse ,Events ,Many ,Rade ,Chile ,Treatment ,N Azn Gb0009895292 ,